Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of butaselen in fibrosing interstitial lung disease
ChiCTR2600120535Phase 2Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Mar 2026
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BS1801 in pulmonary fibrosis (PF), idiopathic interstitial pneumonia (IIP), idiopathic nonspecific interstitial pneumonia (NSIP) and 7 more (5 arms), sponsored by China-Japan Friendship Hospital. Primary endpoints: Adverse events at week 24, Serious adverse events at week 24 and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
BS1801
03
Conditions
pulmonary fibrosis (PF)idiopathic interstitial pneumonia (IIP)idiopathic nonspecific interstitial pneumonia (NSIP)cryptogenic organizing pneumonia (COP)desquamative interstitial pneumonia (DIP)
Beyond the preview
Go deeper on ChiCTR2600120535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120535.